Federica Perdoni

Federica Perdoni

Auto-generated profile, based on publicly available information

Federica Perdoni

Department of Health Sciences, Università degli Studi di Milano, Polo Universitario San Paolo, Blocco C, ottavo piano, via di Rudinì 8, 20142, Milan, Italy.

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2014 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
LSLeighann Sherry
Leighann Sherry
RRRanjith Rajendran
Ranjith Rajendran
DLDavid F Lappin
David F Lappin
EBElisa Borghi
Elisa Borghi
FPFederica Perdoni
Federica Perdoni
GRGordon Ramage
Gordon Ramage
Candida albicans infections have become increasingly recognised as being biofilm related. Recent studies have shown that there is a relationship between biofilm formation and poor clinical outcomes in patients infected with biofilm proficient strains. Here we have investigated a panel of clinical isolates in an attempt to evaluate their phenotypic and transcriptional properties in an attempt to differentiate and define levels of biofilm formation.

18 July 2014 in European Journal of Histochemistry
Verified
Journal Article
Open access
PDF file
FPF. Perdoni
F. Perdoni
MFM. Falleni
M. Falleni
DTDelfina Tosi
Delfina Tosi
CDCirasola D
Cirasola D
SRS. Romagnoli
S. Romagnoli
EBElisa Borghi
Elisa Borghi
A histological procedure to study fungal infection in the wax moth Galleria mellonella

30 October 2015 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
FPFederica Perdoni
Federica Perdoni
PSPaola Signorelli
Paola Signorelli
DCDaniela Cirasola
Daniela Cirasola
ACAnna Caretti
Anna Caretti
VGValentina Galimberti
Valentina Galimberti
EBElisa Borghi
Elisa Borghi
The human pathogenic mold Aspergillus fumigatus is able to form a complex biofilm embedded in extracellular matrix. Biofilms confer antimicrobial resistance and it is well known that aspergillosis is often refractory to the conventional antifungal therapy. The treatment of biofilm-related infections poses a significant clinical challenge on a daily basis, promoting the search for new therapeutic agents. Our aim was to exploit the modulation of sphingolipid mediators as new therapeutic target to overcome antifungal resistance in biofilm-related infections. Antifungal susceptibility testing was performed on 20 clinical isolates of Aspergillus fumigatus and one reference strain (A. fumigatus Af293) according the EUCAST protocol. Sessile MICs were assessed on 24-h preformed-biofilm by means of XTT-reduction assay. Myriocin (0.25–64 mg/L), a commercial sphingolipid synthesis inhibitor, was used. The MEC50 value (mg/L) of Myriocin was 8 (range 4–16) for both planktonic and sessile cells. Drug-induced morphological alterations were analyzed by optical and electron microscopy (TEM) on 24h preformed A. fumigatus Af293 biofilms. An evident hyphal damage, resulting in short, stubby, and highly branched hyphae was observed by optical microscopy. At 24h, TEM studies showed important morphological alterations, such as invaginations of the cell membrane, modification in the vacuolar system and presence of multilamellar bodies, in some cases within vacuoles. The direct antifungal activity, observed on both planktonic and sessile fungi, suggests that inhibition of sphingolipid synthesis could represent a new target to fight biofilm-related A. fumigatus resistance.